Skip to main content
Premium Trial:

Request an Annual Quote

Universal Biosensors Licenses SpeeDx's MNAzyme Tech for Point-of-Care MDx Apps


Australian diagnostics firm Universal Biosensors said this week that it has non-exclusively licensed fellow Aussie firm SpeeDx's proprietary MNAzyme technology for use in molecular diagnostics applications.

The technology is a "sensitive and highly selective" method for detecting DNA and RNA and, when combined with UBI's diagnostic biosensor technology, will enable the development of a molecular diagnostic platform "that can deliver rapid, low-cost results at the point of care," UBI said.

Financial terms of the deal were not disclosed.

UBI, based in Rowville, Victoria, is developing a range of in vitro diagnostic tests for point-of-care use on a technology platform that uses an electrochemical cell that can be adapted for multiple analytes and provide enhanced measurements in whole blood, the company said.

Earlier this month UBI announced a partnership with Siemens Healthcare Diagnostics to develop and commercialize products for the point-of-care coagulation testing market. Paul Wright, CEO of UBI, said that as a result of that deal and the SpeeDx agreement that the company is well positioned to pursue further opportunities in molecular diagnostics.

"Performing molecular diagnostics at the point of care would have significant advantages for patients, and [UBI] is looking forward to addressing this unmet need by developing low-cost, rapid tests," he said.

Sydney-based SpeeDx spun out in 2009 from a Johnson & Johnson Australian research subsidiary to commercialize multi-component nucleic acid enzymes, or MNAzymes, a class of enzymes that it claims provides significant advantages over current enzymes for multiplex qPCR applications.

In April, a company official told PCR Insider that SpeeDx was seeking to license the MNAzymes to third parties for qPCR applications such as human in vitro diagnostics, veterinary medicine, and environmental and food testing. The official also indicated at the time that SpeeDx was eyeing collaborations with undisclosed third parties to bring point-of-care instruments and assays based on the enzymes to the human IVD market (PCR Insider 4/1/10).

SpeeDx also sells an MNAzyme-based kit to measure DNA extraction efficiency in Australia and New Zealand through research tools developer and distributor Bioline.

Filed under

The Scan

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.

Sequencing Analysis Examines Gene Regulatory Networks of Honeybee Soldier, Forager Brains

Researchers in Nature Ecology & Evolution find gene regulatory network differences between soldiers and foragers, suggesting bees can take on either role.

Analysis of Ashkenazi Jewish Cohort Uncovers New Genetic Loci Linked to Alzheimer's Disease

The study in Alzheimer's & Dementia highlighted known genes, but also novel ones with biological ties to Alzheimer's disease.

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.